Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes
To evaluate response rate of cisplatin - metronomic cyclophosphamide treatment.
Metastatic Breast Cancer
DRUG: Cisplatin|DRUG: Metronomic Cyclophosphamide
Response rate of cisplatin - metronomic cyclophosphamide treatment, 18 months and 6 weeks
Disease free progression, 3 years|safety profile of cisplatin - metronomic cyclophosphamide association, Number of Participants with Adverse Events, 18 months and 6 weeks|Overall survival, 5 years|Predictive factors to response and/or resistance treatment, 18 months and 6 weeks
To evaluate response rate of cisplatin - metronomic cyclophosphamide treatment.